The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma (TACTICS-L) in Japan: Final analysis.
 
Kazuomi Ueshima
Honoraria - Bayer; Chugai Pharma; EA Pharma; Eisai; Kowa; Lilly Japan; MSD; Sumitomo Group; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Lilly Japan; Pfizer; Takeda; Takeda
 
Toru Ishikawa
No Relationships to Disclose
 
Issei Saeki
No Relationships to Disclose
 
Naoki Morimoto
Research Funding - Abbvie; Eisai
 
Hiroshi Aikata
Honoraria - Eisai
Research Funding - Eisai
 
Nobukazu Tanabe
No Relationships to Disclose
 
Yoshitaka Inaba
No Relationships to Disclose
 
Yoshiyuki Wada
No Relationships to Disclose
 
Yasuteru Kondo
No Relationships to Disclose
 
Masahiro Tsuda
No Relationships to Disclose
 
Kazuhiko Nakao
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; Micron; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Michihisa Moriguchi
Consulting or Advisory Role - Bayer Yakuhin; Chugai Pharma; Eisai; Lilly Japan
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Eisai; Lilly Japan
Research Funding - Bayer Yakuhin; Bristol-Myers Squibb; Eisai; MSD K.K
 
Takanori Ito
No Relationships to Disclose
 
Masahiro Kobayashi
Honoraria - Eisai
 
Hironori Koga
No Relationships to Disclose
 
Keisuke Hino
No Relationships to Disclose
 
Yoshiyuki Suzuki
No Relationships to Disclose
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Nihonkayaku; Novartis; Otsuka; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - BrightPath Biotheraputics; Nippon Shinyaku
 
Masatoshi Kudo
Honoraria - Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Lilly Japan; MSD
Consulting or Advisory Role - BMS; Eisai; MSD; Ono Pharmaceutical; Roche
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Ono Pharmaceutical; Otsuka (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)